Making an appropriate judgment on the relevance and validity of a drug concept is an essential part of “translational science,” which bridges the gap between basic science and the clinic in the development of new drugs.
The exploratory pharmacology team is mainly responsible for the identification of new drug targets and the clarification of overall quality of drug candidates in kidney, skin, and immunological diseases. To this end, we construct in vitro and in vivo assay systems to analyze the function and involvement of drug targets in the pathological process of these diseases, and to understand the mode of actions of the drug candidate at the gene, protein, cell, tissue, and whole-organism or identical level. Estimation of clinical efficacy is crucially important; we therefore are also actively involved in the establishment of validated and predictive animal models and the identification of biomarkers for the drug candidate in cooperation with internal and external researchers. Furthermore, we put our effort in additional indication surveys to maximize the adaptability of drug candidates and increase the success of their clinical trials.